Loading clinical trials...
Loading clinical trials...
GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability of 2 doses of GW823...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
GlaxoSmithKline
NCT06613854 · Type 2 Diabetes Mellitus (T2DM)
NCT07232537 · Chronic Kidney Disease, Type 2 Diabetes Mellitus
NCT06278207 · Chronic Kidney Disease, Type 2 Diabetes Mellitus
NCT06810635 · Type 2 Diabetes Mellitus (T2DM)
NCT07051005 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM)
GSK Clinical Trials Call Center
Tallassee, Alabama
GSK Clinical Trials Call Center
Phoenix, Arizona
GSK Clinical Trials Call Center
Tucson, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions